Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation.

Sakizci Uyar, Bahar; Ensarioglu, Kerem; Kurt, E Bahar; Özkan, Derya; Özbal Günes, Serra.

Afiliação

Sakizci Uyar B; Department of Anesthesiology and Reanimation, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Ensarioglu K; Department of Pulmonary Medicine, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Kurt EB; Department of Pulmonary Medicine, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Özkan D; Department of Anesthesiology and Reanimation, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Özbal Günes S; Department of Radiology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Turk J Anaesthesiol Reanim ; 50(3): 228-231, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35801331

ABSTRACT

Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article